-
BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards
•
On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was taken into custody by regulatory authorities for cooperation with an ongoing investigation. Yin Min joined BeiGene in January 2022 after spending 15 years at AstraZeneca (AZ, NASDAQ: AZN), where she held several key positions, including…
-
Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities
•
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key executives, including Ms. Xiong Hui, the actual controller, chairman, and general manager, Mr. Xiong Jun, the actual controller, director, and deputy general manager, and Mr. Xue Yuwei, the deputy general manager, have been placed under…
-
Rightongene Bio Receives NMPA Approval for BCR-ABL P210 Fusion Gene Detection Kit
•
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a biopharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its BCR-ABL P210 fusion gene detection kit, which uses the fluorescence reverse transcription polymerase chain reaction (RT-PCR) method. The kit is…
